Cover Image
市場調查報告書

α-突觸核蛋白:開發中產品分析

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365788
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
α-突觸核蛋白:開發中產品分析 Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 93 Pages
簡介

本報告提供以α-突觸核蛋白為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

α-突觸核蛋白 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AC Immune SA
  • AFFiRiS AG
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • NeuroPhage Pharmaceuticals, Inc.
  • Neuropore Therapies, Inc.
  • nLife Therapeutics, S.L.
  • Primary Peptides, Inc.
  • Prothena Corporation Plc
  • QR Pharma, Inc.
  • reMYND NV
  • Synovo GmbH

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0909TDB

Summary:

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 37 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 21, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Alzheimer's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neurodegenerative Diseases, Lewy body Dementia, Amyloidosis, Constipation, Familial Amyloid Neuropathies, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Huntington Disease, Schizophrenia, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.

The latest report Alpha Synuclein - Pipeline Review, H2 2017, outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
  • The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
    • Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
    • AC Immune SA
    • AFFiRiS AG
    • BioArctic AB
    • Biogen Inc
    • Evotec AG
    • Genmab A/S
    • H. Lundbeck A/S
    • ICB International Inc
    • MedImmune LLC
    • Neuropore Therapies Inc
    • nLife Therapeutics SL
    • Prothena Corp Plc
    • QR Pharma Inc
    • reMYND NV
  • Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
    • ABL-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-1947D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-1948D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-1949D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-1950D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-1950R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAN-0805 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIIB-054 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLR-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPC-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Parkinson's disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LuAF-82422 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-1341 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLFPD-1233 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-20011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-289 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-3G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT100-18A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Posiphen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • quinpramine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReS-9S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trehalose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
  • Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 08, 2017: Anti-Alpha-Synuclein Antibody is a Potential Disease-Modifying Treatment for Parkinson's Disease
      • Jun 07, 2017: AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE PD03A, Confirming Immunogenicity and Safety Profile in Parkinson's Disease Patients
      • May 15, 2017: Enterin's RASMET Study Enrolls First Patient With Parkinson's Disease
      • Apr 02, 2017: Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease
      • Mar 28, 2017: Biogen to Present Data on BIIB054 at the 13th International Conference on Alzheimer's and Parkinson's Diseases
      • Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference
      • Mar 09, 2017: Results for Prothena's Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson's Disease to be Presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases
      • Dec 13, 2016: First-In-Human Assessment of PRX002, Prothenas Anti-Alpha Synuclein Antibody for Parkinson's Disease, Published in Movement Disorders Journal
      • Nov 18, 2016: Proclara Biosciences Awarded Part the Cloud Grant from Alzheimers Association to Support Development of NPT088 for Alzheimer's Disease
      • Nov 16, 2016: Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders
      • Nov 09, 2016: Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease
      • Sep 07, 2016: Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer's Disease
      • Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11
      • Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials
      • Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1)
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AC Immune SA, H2 2017
  • Pipeline by AFFiRiS AG, H2 2017
  • Pipeline by BioArctic AB, H2 2017
  • Pipeline by Biogen Inc, H2 2017
  • Pipeline by Evotec AG, H2 2017
  • Pipeline by Genmab A/S, H2 2017
  • Pipeline by H. Lundbeck A/S, H2 2017
  • Pipeline by ICB International Inc, H2 2017
  • Pipeline by MedImmune LLC, H2 2017
  • Pipeline by Neuropore Therapies Inc, H2 2017
  • Pipeline by nLife Therapeutics SL, H2 2017
  • Pipeline by Prothena Corp Plc, H2 2017
  • Pipeline by QR Pharma Inc, H2 2017
  • Pipeline by reMYND NV, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top